GlassScriptPhysician profile
Ravi S Chander
NPI 1578511598
$4,420.69
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $329 · 2021: $1,121 · 2022: $1,005 · 2023: $361 · 2024: $17.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.47 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $778.47 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $685.38 | 2022 | |
| Abbvie INC. | $401.57 | 2019-2022 | |
| Biogen, INC. | $234.92 | 2019-2021 | |
| Emd Serono, INC. | $231.88 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $222.82 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $221.91 | 2019-2021 | |
| Pfizer INC. | $219.03 | 2023 | |
| Sumitomo Pharma America, INC. | $159.44 | 2023-2024 | Aptiom |
| Ucb, INC. | $155.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $140.40 | 2019 | |
| Genzyme Corporation | $134.92 | 2019-2020 | |
| Amgen INC. | $105.32 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $92.35 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $79.52 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $77.00 | 2022 | |
| Acorda Therapeutics, INC | $64.72 | 2019 | |
| Supernus Pharmaceuticals, INC. | $49.57 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.91 | 2020 | |
| Eisai INC. | $45.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.67 | 2022 | |
| Abbott Laboratories | $32.28 | 2019 | |
| Genentech USA, INC. | $30.29 | 2019 | |
| Kyowa Kirin, INC. | $29.70 | 2019 | |
| Allergan, INC. | $24.90 | 2021 | |
| Mallinckrodt Enterprises LLC | $21.57 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.00 | 2019 | |
| Daiichi Sankyo INC. | $17.11 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.65 | 2019 | |
| Strongbridge US INC. | $12.46 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Boston Scientific Corporation | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Chander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.